OMERACT 2016 — International Consensus Conference on Outcome Measures in Rheumatology Clinical Trials

In May of 2016, the biennial Outcome Measures in Rheumatology (OMERACT) Conference took place in Whistler, British Columbia, Canada. OMERACT is an international network of health professionals focused on outcome measurement across randomized controlled trials and longitudinal observational studies. The objective of OMERACT is to improve outcome measures through a data-driven, iterative consensus process. At OMERACT's biennial international meetings, participants gather in a collegial interactive environment to develop core sets of patient-important outcomes for clinical studies in rheumatology.

OMERACT has published over 1000 peer-reviewed articles. It has 42 active working groups (Table 1). The number grows with every meeting, demonstrating the continuing need for this work.

OMERACT has published 10 core outcome sets [ankylosing spondylitis, fibromyalgia, gout (acute and chronic), systemic lupus erythematosus, osteoarthritis, osteoporosis, psoriatic arthritis (PsA), rheumatoid arthritis (RA), vasculitis] — the evidence is accumulating that their uptake in published clinical trials is increasing, for example, the RA Core Set is now used in over 80% of published RA trials (www.bmj.com/content/357/bmj.j2262).

The 2016 Whistler meeting was a success, with nearly 200 participants intensively participating in 5 workshops: Flare in RA, Polymyalgia Rheumatica, PsA, Antineutrophil Cytoplasmic Antibody Vasculitis, Shared Decision Making, and 16 Special Interest Groups on the program. These consisted of a variety of short presentations and small group discussions, while maintaining the ambiance of a true multidisciplinary, collaborative, friendly yet rigorous process of outcome measure development. Patient contribution continues to play a fundamental part in the OMERACT process; it not only improves the results of OMERACT research, but also gives a new perspective that is clinically relevant to the topic being researched. OMERACT 2016 hosted 21 patients from Australia, Canada, Europe, and the United States. In addition to patients, OMERACT participants came from a range of backgrounds and expertise, including clinicians and rheumatology trainees, clinical outcome methodologists who work in academic environments, regulatory agencies, pharmaceutical and biotech companies, or clinical research organizations. While some OMERACT 2016 participants reside in Canada, the majority of participants of the meeting traveled to Whistler from North America, Europe, Asia, and Australia.

Table 1. OMERACT active Working Groups (n = 42).

Disease

ANCA Vasculitis (Core Set)
Behçet Syndrome
Ankylosing Spondylitis — Reference Case
Connective Tissue Diseases — Interstitial Lung Disease
Fibromyalgia (Core Set)
Flares in Osteoarthritis
Flares in Rheumatoid Arthritis
Glucocorticoid Adverse Events

Gout Hand Osteoarthritis

International Classification of Functioning, Disability and Health Juvenile Inflammatory Arthritis Core Set Large Vessel Vasculitis Myositis

Osteoporosis (Core Set)
Osteoporosis (Core Set)

Pain Polymyalgia Rheumatica (PMR)

Psoriatic Arthritis
Remission in Rheumatoid Arthritis — Patient Perspective
Rheumatoid Arthritis (Core Set)
Shoulder Pain Outcome Measures

Systemic Lupus Erythematosus Total Joint Replacement

Imaging and Biomarkers

Gout Biomarker Group Magnetic Resonance Imaging in Arthritis Juvenile Arthritis Magnetic Resonance Imaging Soluble Biomarkers

Study grouP for x-trEme Computed Tomography in Rheumatoid Arthritis Statistical Analysis of Radiographic Data in Rheumatoid Arthritis Clinical Trials Synovial Tissues in Randomized Clinical Trials

Ultrasound

Methods

Adaptive Clinical Trial Design
Item Response Theory and Computerized Adaptive Testing
Consensus for Consensus
Contextual Factors
Critical Outcomes in Longitudinal Studies
Safety in Rheumatology Clinical Trials Working Group
Equity
Quality-adjusted Life-years
Rasch Model and Minimal Important Difference
Health Literacy
Medication Adherence
Instrumentation Across Diseases
Shared Decision Making
Stiffness
Worker Productivity

 $\label{lem:omeracond} OMERACT: Outcome\ Measures\ in\ Rheumatology;\ ANCA:\ antineutrophil\ cytoplasmic\ antibody.$

Personal non-commercial use only. The Journal of Rheumatology Copyright © 2017. All rights reserved.

One major focus of the meeting was the operationalization of the instrument selection part of the new OMERACT Filter 2.0 that incorporates a number of clinimetric advances that have occurred since the original OMERACT Filter. Truth, discrimination, and feasibility continue to be the pillars of the OMERACT Filter unique to OMERACT, but as part of the transition to the new Filter 2.1, to select the most promising instruments, participants presented data more detailed than previously on concept match (content validity and face validity of "truth") and feasibility (practical aspects of length, time to complete, burden, difficulty, and cost). After small group discussions, draft recommendations were brought to a plenary for a vote at this stage. We called this an "eyeball vote" because it was the first scan of the potential for this instrument.

Three Working Groups brought instruments forward at this stage: Flare RA, PsA, and ANCA Vasculitis. All received the votes they needed to move forward into a full review of published evidence and/or creation of evidence as needed for the OMERACT Filter. Based on feedback from the OMERACT community, this "eyeball vote" will be integrated into a more streamlined 1-stage process (watch for Filter 2.1).

Dissemination and promoting uptake of core sets known as "knowledge translation" was another major focus of the meeting. Led by 2 international leaders, Dr. Sean Tunis and Dr. Ian Graham in a special workshop, participants were invited to propose and discuss recommendations for the OMERACT community to (1) strengthen stakeholder involvement in the core outcome set development process, and (2) promote dissemination and implementation of core outcome sets with a specific focus on the potential role of post-regulatory decision makers.

Additional information and publications by Working Groups can also be found in The OMERACT Handbook. The OMERACT Handbook, which contains both methodological and organizational information (currently available on the OMERACT Website: www.omeract.org), has encouraged participants to become more engaged with the process by explaining various OMERACT procedures and practices. The OMERACT Handbook is currently being reviewed, and soon an updated version will be available (www.omeract.org) and will continue as a major reference resource for all those interested in outcome measure development.

PETER TUGWELL, MD, MSc,

Department of Medicine, Faculty of Medicine,

University of Ottawa, and

Ottawa Hospital Research Institute, Clinical Epidemiology Program, and School of Epidemiology, Public Health, and Preventive Medicine, Faculty of Medicine,

University of Ottawa,

Ottawa, Ontario, Canada;

SHAWNA GROSSKLEG, Secretariat, OMERACT,

University of Ottawa,

Ottawa, Ontario, Canada;

BEVERLEY SHEA, PhD,

School of Epidemiology, Public Health, and Preventive Medicine, Faculty of Medicine,

University of Ottawa, and

Ottawa Hospital Research Institute, Clinical Epidemiology Program, Ottawa, Ontario, Canada;

DORCAS BEATON, BScOT, PhD,

Musculoskeletal Health and Outcomes Research,

St. Michael's Hospital, and

Institute for Work and Health, and

Department of Occupational Science and Occupational Therapy, Rehabilitation Sciences Institute and the Institute for Health Policy Management and Evaluation,

University of Toronto,

Toronto, Ontario, Canada;

GEORGE A. WELLS, MSc, PhD, Director,

Cardiovascular Research Methods Centre,

University of Ottawa Heart Institute, and

Professor, Department of Epidemiology and Community Medicine, University of Ottawa,

Ottawa, Ontario, Canada.

OMERACT receives arms-length funding from 36 companies. Address correspondence to S. Grosskleg, OMERACT, 43 Bruyère St., Annex E, Ottawa, Ontario K1N 5C7, Canada. E-mail: admin@omeract.org

ACKNOWLEDGMENT

The OMERACT conferences are possible only through the ongoing voluntary commitment of the chairs and their working groups, to whom we are grateful. A special thank you goes to Valorie Thompson and Andrea Speckin (Innovations Consulting Group) for organizing the logistics and running the conference.

Many universities and granting agencies provided financial support for the participation of delegates. The Organizing Committee thanks the European League Against Rheumatism and the Australian Rheumatology Association for bursaries provided to enable young researchers to attend the OMERACT meeting. Financial support for OMERACT 2016 was provided by the following pharmaceutical companies and their subsidiaries: Abbvie, USA; Amgen, USA; Astra Zeneca, UK; Bristol Myers Squibb, USA; Celgene, USA; Centrexion, USA; Eli Lilly, USA; Gruenthal, the Netherlands; Horizon Pharma Inc., USA; Janssen, USA; Novartis, Switzerland; Pfizer, USA; Quintiles, Netherlands; Roche, USA; and UCB, USA.

J Rheumatol 2017;44:1511-14; doi:10.3899/jrheum.170659



OMERACT 2016 — International Consensus Conference on Outcome Measures in Rheumatology Clinical Trials

EXECUTIVE COMMITTEE

Dorcas Beaton, Canada

Clifton Bingham, USA
Philip G. Conaghan, UK
Maria-Antonietta D'Agostino, France
Maarten de Wit, Netherlands
Laure Gossec, France
Lyn M. March, Australia
Jasvinder A. Singh, USA
Peter Tugwell, Canada
Lee Simon, USA
Vibeke Strand, USA
George A. Wells, Canada

OMERACT 2016 ORGANIZING COMMITTEE

Dorcas Beaton, Canada Shawna Grosskleg, Canada Cathy Hofstetter, Canada Anne Lyddiatt, Canada Bev Shea, Canada Peter Tugwell, Canada George A. Wells, Canada

SCIENTIFIC ADVISORY COMMITTEE

Arvind Chopra
Dan Furst
Desires van der l

Desiree van der Heijde Eduardo Samoyoa

Tugwell, et al: Introduction

Ernest Choy Girish Mody Janet Woodcock Josef Smolen Ken Saag Maarten Boers Maxime Dougados Niti Goel

Pam Richards
Pamela Montie
Paul Emery
Peter Brooks
Peter Merkel
Phil Mease
Robert Landewe
Sherine Gabriel

DELEGATES

William Taylor

Ted Pincus

Evo Alemao Helene Alexanderson Rieke Alten

Rieke Alten Jaclyn Anderson Omar Azmat Nick Bansback Skye Barbic Cheryl Barnabe Christie Bartels Susan Bartlett Jennifer Barton Dorcas Beaton Clifton Bingham Paul Bird

Rachel Black Maarten Boers Annelies Boonen Peter Brooks Rachelle Buchbin

Rachelle Buchbinder Andrew Burghardt Vivian Bykerk Mark Campbell Loreto Carmona

Maria Casal Dominguez

Connie Chen
Peter Choong
Ernest Choy
Robin Christensen
Lisa Christopher-Stine
Philip Conaghan
Alessandro Consolaro

Maria-Antonietta D'Agostino

1513

Nemanja Damjanov Maarten de Wit Amy DeLozier Haner Direskeneli Andrea Doria Michelle Dowsey Kristina Duffin Hani El-Gabalawy

Personal non-commercial use only. The Journal of Rheumatology Copyright © 2017. All rights reserved.

Musaab ElmamounDiane LacailleIlfita SahbudinSait Burak ErerRobert LandeweAhmed SamadDaniel Eric FurstChristine LindsayWolfgang Schmidt

Sinem Nihal Esatoglu

Bruno Fautrel

Maria Lopez-Olivo

Heidi Siddle

Andrew Filer

Sarah Mackie

Earl Silverman

Monika Finger

Silvia Magni Manzoni

Lee Simon

Stephanie Finzel

Alfred Mahr

Jasvinder Singh

Oliver FitzGerald Walter Maksymowych Premarani Sinnathurai Caroline Flurey Lyn M. March Victor Sloan Joel Gagnier Lara Maxwell Yeong Wook Song

Frederique Gandjbakhch Alexa Meara Benjamin Soule
Dafna Gladman Philip Mease Antoine Sreih
Daniel Glinatsi Peter Merkel Ilona Steigerwald
Charlie Goldsmith Mihaela Cosmina Micu Maria Simona Stoenoiu

Susan Goodman Nataliya Milman Kathryn Stok
Laure Gossec Esi Morgan Bradley Stolshek
Shawna Grosskleg Jane Munro Vibeke Strand
Ahmet Gul April Naegeli Maria Suarez-Almazor
Serena Halls Jan Michael Nebesky Marcin Szkudlarek

Serena Halls
Jan Michael Nebesky
Marcin Szkudlarek
Gulen Hatemi
Merrilee Needham
Lene Terslev
Sarah Hewlett
Linda Nelsen
Caroline Terwee
Catherine Hill
Stanton Newman
William Tillett
Pil Hojgaard
Dianne Nguyen
Zahi Touma
Robert Halt
Alexis Ordie
Karine Tounin-Apri

Robert Holt Alexis Ogdie Karine Toupin-April
Hsiaomin Huang Sarah Ohrndorf Logan Trenaman
Susan Humphrey-Murto Dana Orange Mona Trivedi
Annamaria Iagnocco Ana-Maria Orbai Peter Tugwell
Kei Ikeda Mikkel Ostergaard Sean Tunis

Francesca Ingegnoli Yesim Ozguler Nikolay Tzaribachev Jacob Jaremko Matthew Page Desiree van der Heijde Elizabeth Jernberg Jin Kyun Park Marion van Rossum Steffen Jugl Charles Peterfy Lilian van Tuvl Susanne Juhl Pedersen Jennifer Petkovic Arianne Verhagen Ulrike Kaiser Kristine Phillips Richard Vesely Sevil Kamali Violeta Maria Vlad Carlos Pineda Christoph Pohl Jelena Vojinovic

Tatsuo Kanazawa George Wells Chetan Karvekar Linda Rasch Yasuhiro Katsumata James Witter Viviana Ravagnani Helen Keen Malin Regardt Thasia Woodworth William Reiss Tanaz Kermani Yusuf Yazici Ergun Kizilocak Bethan Richards Sarah Yim

Louise KlokkerMeredith RiebschlegerLeung (Katy) Ying YingMargreet KloppenburgJoanna RobsonNatalia Viviana Zamora

Marion Kortekaas

Articles presented at the OMERACT 2016 Conference, Whistler, British Columbia, Canada, May 2016

- Part 1: Introduction, Workshops, Special Sessions
 - Part 2: Special Interest Groups, Part 1
 - Part 3: Special Interest Groups, Part 2

Part 2 will appear in the November issue.

Personal non-commercial use only. The Journal of Rheumatology Copyright © 2017. All rights reserved.